The property developer took part in a $68.4m round that will help Juventas advance its clinical-stage oncology cell therapy candidates.
China-based immunotherapy developer Juventas has raised RMB450m ($68.4m) in a funding round led by private equity fund CMG-SDIC Capital and backed by commercial property developer Parkland Group, DealStreetAsia reported yesterday. The round included Kaixin Biotechnology – possibly part of automotive retailer Kaixin Auto – Tzitzit Asset, Tianjin Venture Capital, Ruisheng Investment, Xiangrong Capital, Dalton Venture…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.